Review Article
Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept
Table 1
Trials of oral EGFR tyrosine kinase inhibitors.
| | Phase | Number of patients | Anatomic site | Histology | Treatment regimen | Outcomes | Comments |
| Ferry et al. [8] | II | 27 | Esophagus | 27/27 adenocarcinoma | Gefitinib 500 mg PO daily | mOS 4.5 months mPFS 1.9 months 3/27 PR (11%) 7/27 SD (26%) | Prior chemotherapy: 18/27 (67%) | Janmaat et al. [9] | II | 36 | Esophagus | 26/36 adenocarcinoma (72%) 9/36 squamous cell (25%) 1/36 adenosquamous (3%) | Gefitinib 500 mg PO daily | mOS 5.5 months mPFS 2 months 1/36 PR (3%) 10/36 SD (28%) | Second-line treatment 8/36 not assessable for response | Dragovich et al. [10] | II | 70 | 26/70 Gastric (37%) 44/70 GEJ (63%) | 70/70 adenocarcinoma | Erlotinib 150 mg PO daily | mOS GEJ 6.7 months mOS Gastric 3.5 months mTTF GEJ 2 months mTTF Gastric 1.6 months GEJ: 1/43 CR (2%), 3/43 PR (7%), 5/43 SD (12%) | All responses in esophageal GEJ cohort No responses seen in the gastric cohort | Hecht et al. [11] | II | 25 | 13/25 GEJ (52%) 12/25 Esophagus (48%) | 25/25 adenocarcinoma | Lapatinib 1000–1500 mg PO daily | No responses seen 2/25 SD (8%) | Elevated TGF-alpha expression correlated with shorter TTP |
|
|